AP NEWS

Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors - Pipeline Insights, 2018 - ResearchAndMarkets.com

November 30, 2018

DUBLIN--(BUSINESS WIRE)--Nov 30, 2018--The “Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors -Pipeline Insights, 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors.The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type

Pipeline Products covered across the following Developmental Stages:

ClinicalNon-clinicalInactive: Discontinued and/or Dormant

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

The report assesses the active Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors pipeline products by developmental stage, product type, molecule type, and administration route.

Scope

The report provides a snapshot of the pipeline development for Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical informationProvides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors The report also covers the dormant and discontinued pipeline projects related to the Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors Companies FeaturedIonis PharmaceuticalH3 Biomedicine IncDaiichi Sankyo Inc.Blueprint Medicines Corp.Incyte CorporationGenoscoAstraZenecaEli Lilly

Key Topics Covered

1. Report Introduction

2. Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors -Pipeline Insights, 2018 Overview

3. Pipeline Therapeutics

An Overview of the Market

4. Comparative Analysis

5. Products in Clinical Stage

5.1 Drug Name : Company Name

Product DescriptionResearch and DevelopmentProduct Development Activities

6. Products in Pre-Clinical and Discovery Stage

6.1 Drug Name : Company Name

Product DescriptionResearch and DevelopmentProduct Development Activities

7. Therapeutic Assessment

Assessment by Route of AdministrationAssessment by Stage and Route of AdministrationAssessment by Molecule TypeAssessment by Stage and Molecule Type

8. Inactive Products

8.1 Drug Name : Company Name

Product DescriptionResearch and DevelopmentProduct Development Activities

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/fjtw6t/fibroblast_growth?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181130005345/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Endocrine and Metabolic Disorders Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 11/30/2018 11:43 AM/DISC: 11/30/2018 11:43 AM

http://www.businesswire.com/news/home/20181130005345/en

AP RADIO
Update hourly